Symbols / IDYA Stock $29.65 +4.70% IDEAYA Biosciences, Inc.
IDYA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Ratings
Current target
$29.65
Low
$36.00
High
$81.00
Mean
$52.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-07 | main | Mizuho | Outperform → Outperform | $50 |
| 2026-04-14 | main | Goldman Sachs | Neutral → Neutral | $35 |
| 2026-04-14 | main | Wells Fargo | Overweight → Overweight | $48 |
| 2026-04-14 | main | RBC Capital | Outperform → Outperform | $53 |
| 2026-04-14 | main | Wedbush | Outperform → Outperform | $58 |
| 2026-04-14 | main | Guggenheim | Buy → Buy | $54 |
| 2026-03-31 | reit | Wedbush | Outperform → Outperform | $52 |
| 2026-02-19 | main | Citigroup | Buy → Buy | $65 |
| 2026-02-18 | reit | RBC Capital | Outperform → Outperform | $49 |
| 2026-02-18 | reit | Guggenheim | Buy → Buy | $50 |
| 2026-02-18 | main | Wedbush | Outperform → Outperform | $52 |
| 2026-01-21 | main | RBC Capital | Outperform → Outperform | $45 |
| 2026-01-06 | main | Truist Securities | Buy → Buy | $60 |
| 2025-11-24 | init | Truist Securities | — → Buy | $59 |
| 2025-11-11 | main | Mizuho | Outperform → Outperform | $46 |
| 2025-10-23 | main | JP Morgan | Overweight → Overweight | $79 |
| 2025-10-21 | main | Goldman Sachs | Neutral → Neutral | $30 |
| 2025-10-21 | main | RBC Capital | Outperform → Outperform | $41 |
| 2025-10-21 | reit | BTIG | Buy → Buy | $62 |
| 2025-09-18 | init | Guggenheim | — → Buy | $50 |
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire Fri, 01 May 2026 07
- Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA) - Stock Titan Fri, 15 May 2026 16
- Has The Market Overreacted To Recent Weakness In IDEAYA Biosciences (IDYA) Shares? - Yahoo Finance Mon, 02 Feb 2026 08
- Will Widened Q1 Loss and New Shelf Registration Change IDEAYA Biosciences’ (IDYA) Funding Narrative? - simplywall.st Sat, 16 May 2026 09
- Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha Wed, 08 Apr 2026 07
- Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits Mon, 13 Apr 2026 07
- $IDYA stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Mon, 13 Apr 2026 07
- IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - PR Newswire hu, 30 Apr 2026 07
- Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan Fri, 01 May 2026 07
- Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Yahoo Finance Sun, 03 May 2026 07
- Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality - Seeking Alpha Mon, 13 Apr 2026 07
- IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire ue, 05 May 2026 07
- IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan ue, 05 May 2026 07
- Three experimental cancer programs to watch at April's big AACR meeting - Stock Titan Wed, 18 Mar 2026 07
- IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan Fri, 10 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
218.71
+3024.43%
|
7.00
-70.07%
|
23.39
-54.08%
|
50.93
|
| Operating Revenue |
|
218.71
+3024.43%
|
7.00
-70.07%
|
23.39
-54.08%
|
50.93
|
| Operating Expense |
|
378.02
+13.19%
|
333.98
+111.63%
|
157.81
+39.13%
|
113.43
|
| Research And Development |
|
314.70
+6.80%
|
294.67
+127.53%
|
129.51
+44.64%
|
89.54
|
| Selling General And Administration |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| General And Administrative Expense |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| Other Gand A |
|
63.32
+61.11%
|
39.30
+38.85%
|
28.31
+18.45%
|
23.90
|
| Total Expenses |
|
378.02
+13.19%
|
333.98
+111.63%
|
157.81
+39.13%
|
113.43
|
| Operating Income |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| Total Operating Income As Reported |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| EBITDA |
|
-154.72
+52.12%
|
-323.14
-147.77%
|
-130.42
-121.10%
|
-58.99
|
| Normalized EBITDA |
|
-154.72
+52.12%
|
-323.14
-147.77%
|
-130.42
-121.10%
|
-58.99
|
| Reconciled Depreciation |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| EBIT |
|
-159.31
+51.28%
|
-326.98
-143.23%
|
-134.43
-115.08%
|
-62.50
|
| Net Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Pretax Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Non Operating Interest Income Expense |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Net Interest Income |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Interest Income Non Operating |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Interest Income |
|
45.62
-13.11%
|
52.50
+144.54%
|
21.47
+458.05%
|
3.85
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income From Continuing Operation Net Minority Interest |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income From Continuing And Discontinued Operation |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income Continuous Operations |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Normalized Income |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Net Income Common Stockholders |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
2.16
|
| Diluted EPS |
|
-1.28
+61.90%
|
-3.36
-71.43%
|
-1.96
-38.03%
|
-1.42
|
| Basic EPS |
|
-1.28
+61.90%
|
-3.36
-71.43%
|
-1.96
-38.03%
|
-1.42
|
| Basic Average Shares |
|
88.49
+8.33%
|
81.68
+42.00%
|
57.52
+38.79%
|
41.44
|
| Diluted Average Shares |
|
88.49
+8.33%
|
81.68
+42.00%
|
57.52
+38.79%
|
41.44
|
| Diluted NI Availto Com Stockholders |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
649.32
|
| Current Assets |
|
532.63
|
| Cash Cash Equivalents And Short Term Investments |
|
525.11
|
| Cash And Cash Equivalents |
|
157.02
|
| Other Short Term Investments |
|
368.10
|
| Receivables |
|
0.02
|
| Accounts Receivable |
|
0.02
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
—
|
| Other Current Assets |
|
7.50
|
| Total Non Current Assets |
|
116.68
|
| Net PPE |
|
8.41
|
| Gross PPE |
|
18.02
|
| Accumulated Depreciation |
|
-9.61
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
1.00
|
| Other Properties |
|
13.70
|
| Leases |
|
3.32
|
| Investments And Advances |
|
107.49
|
| Other Non Current Assets |
|
0.78
|
| Total Liabilities Net Minority Interest |
|
28.23
|
| Current Liabilities |
|
27.10
|
| Payables And Accrued Expenses |
|
25.35
|
| Payables |
|
6.60
|
| Accounts Payable |
|
6.60
|
| Current Accrued Expenses |
|
18.76
|
| Current Debt And Capital Lease Obligation |
|
1.75
|
| Current Capital Lease Obligation |
|
1.75
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
1.12
|
| Long Term Debt And Capital Lease Obligation |
|
1.12
|
| Long Term Capital Lease Obligation |
|
1.12
|
| Non Current Deferred Liabilities |
|
0.00
|
| Non Current Deferred Revenue |
|
0.00
|
| Stockholders Equity |
|
621.09
|
| Common Stock Equity |
|
621.09
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
65.04
|
| Ordinary Shares Number |
|
65.04
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
968.88
|
| Retained Earnings |
|
-348.36
|
| Gains Losses Not Affecting Retained Earnings |
|
0.56
|
| Other Equity Adjustments |
|
0.56
|
| Total Equity Gross Minority Interest |
|
621.09
|
| Total Capitalization |
|
621.09
|
| Working Capital |
|
505.53
|
| Invested Capital |
|
621.09
|
| Total Debt |
|
2.87
|
| Capital Lease Obligations |
|
2.87
|
| Net Tangible Assets |
|
621.09
|
| Tangible Book Value |
|
621.09
|
| Available For Sale Securities |
|
107.49
|
| Investmentin Financial Assets |
|
107.49
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-71.10
+71.28%
|
-247.58
-114.87%
|
-115.22
-32.18%
|
-87.17
|
| Cash Flow From Continuing Operating Activities |
|
-71.10
+71.28%
|
-247.58
-114.87%
|
-115.22
-32.18%
|
-87.17
|
| Net Income From Continuing Operations |
|
-113.70
+58.58%
|
-274.48
-142.98%
|
-112.96
-92.59%
|
-58.66
|
| Depreciation Amortization Depletion |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Depreciation |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Depreciation And Amortization |
|
4.59
+19.80%
|
3.83
-4.34%
|
4.01
+14.03%
|
3.52
|
| Stock Based Compensation |
|
46.12
+32.72%
|
34.75
+87.93%
|
18.49
+58.99%
|
11.63
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
1.87
-83.82%
|
11.55
+187.42%
|
-13.21
+69.26%
|
-42.97
|
| Change In Receivables |
|
0.00
|
0.00
-100.00%
|
0.19
-78.36%
|
0.89
|
| Changes In Account Receivables |
|
0.00
|
0.00
-100.00%
|
0.19
-78.36%
|
0.89
|
| Change In Prepaid Assets |
|
-7.84
-27.29%
|
-6.16
-201.17%
|
-2.04
+3.49%
|
-2.12
|
| Change In Payables And Accrued Expense |
|
13.12
-31.19%
|
19.07
+346.70%
|
4.27
-33.65%
|
6.44
|
| Change In Accrued Expense |
|
10.43
-3.40%
|
10.79
+560.18%
|
1.64
-64.24%
|
4.57
|
| Change In Payable |
|
2.70
-67.43%
|
8.28
+214.23%
|
2.63
+41.36%
|
1.86
|
| Change In Account Payable |
|
2.70
-67.43%
|
8.28
+214.23%
|
2.63
+41.36%
|
1.86
|
| Change In Other Working Capital |
|
-5.97
|
—
|
-13.75
+70.41%
|
-46.48
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
1.41
|
| Change In Other Current Liabilities |
|
2.56
+286.78%
|
-1.37
+26.87%
|
-1.87
-10.18%
|
-1.70
|
| Investing Cash Flow |
|
69.98
+113.92%
|
-502.56
-217.16%
|
-158.46
-374.36%
|
-33.40
|
| Cash Flow From Continuing Investing Activities |
|
69.98
+113.92%
|
-502.56
-217.16%
|
-158.46
-374.36%
|
-33.40
|
| Net PPE Purchase And Sale |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Purchase Of PPE |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Capital Expenditure |
|
-2.37
+38.61%
|
-3.86
-62.88%
|
-2.37
+31.22%
|
-3.44
|
| Net Investment Purchase And Sale |
|
72.34
+114.51%
|
-498.70
-219.50%
|
-156.09
-420.97%
|
-29.96
|
| Purchase Of Investment |
|
-607.89
+48.97%
|
-1,191.31
-99.89%
|
-595.98
-132.98%
|
-255.81
|
| Sale Of Investment |
|
680.23
-1.79%
|
692.61
+57.45%
|
439.89
+94.77%
|
225.85
|
| Financing Cash Flow |
|
29.78
-95.60%
|
677.55
+86.80%
|
362.72
+273.30%
|
97.17
|
| Cash Flow From Continuing Financing Activities |
|
29.78
-95.60%
|
677.55
+86.80%
|
362.72
+273.30%
|
97.17
|
| Net Common Stock Issuance |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Proceeds From Stock Option Exercised |
|
4.92
-78.89%
|
23.32
-55.96%
|
52.95
+2303.72%
|
2.20
|
| Changes In Cash |
|
28.66
+139.48%
|
-72.59
-181.53%
|
89.04
+480.27%
|
-23.41
|
| Beginning Cash Position |
|
85.18
-46.01%
|
157.78
+129.53%
|
68.74
-25.41%
|
92.15
|
| End Cash Position |
|
113.84
+33.64%
|
85.18
-46.01%
|
157.78
+129.53%
|
68.74
|
| Free Cash Flow |
|
-73.47
+70.78%
|
-251.44
-113.82%
|
-117.59
-29.77%
|
-90.62
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.03
-63.77%
|
0.07
+15.00%
|
0.06
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-9.98
+57.06%
|
-23.23
-101.10%
|
-11.55
-1562.30%
|
-0.69
|
| Common Stock Issuance |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Issuance Of Capital Stock |
|
24.86
-96.20%
|
654.23
+111.20%
|
309.76
+226.20%
|
94.96
|
| Net Preferred Stock Issuance |
|
—
|
9.40
-77.72%
|
42.18
|
0.00
|
| Preferred Stock Issuance |
|
—
|
9.40
-77.72%
|
42.18
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-05 View
- 10-Q2026-05-05 View
- 8-K2026-05-05 View
- 8-K2026-04-13 View
- 8-K2026-04-09 View
- 42026-03-02 View
- 10-K2026-02-17 View
- 8-K2026-02-17 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 8-K2026-01-12 View
- 8-K2026-01-12 View
- 8-K2025-12-12 View
- 8-K2025-12-05 View
- 10-Q2025-11-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|